Source: Antibiotics-basel. Unidade: FM
Subjects: INFECÇÕES POR CLOSTRIDIUM, MORTALIDADE, FATORES DE RISCO, BRASIL
ABNT
ALVES, Joana Darc Freitas et al. Metronidazole for treatment of clostridioides difficile infections in Brazil: a single-center experience and risk factors for mortality. Antibiotics-basel, v. 11, n. 9, 2022Tradução . . Disponível em: https://doi.org/10.3390/antibiotics11091162. Acesso em: 04 ago. 2024.APA
Alves, J. D. F., Yamaguti, A., Mendonca, J. S. de, Gamba, C. de M., Fonseca, C. L., Paraskevopoulos, D. K. S., et al. (2022). Metronidazole for treatment of clostridioides difficile infections in Brazil: a single-center experience and risk factors for mortality. Antibiotics-basel, 11( 9). doi:10.3390/antibiotics11091162NLM
Alves JDF, Yamaguti A, Mendonca JS de, Gamba C de M, Fonseca CL, Paraskevopoulos DKS, Paula AI de, Hosino N, Costa SF, Guimaraes T. Metronidazole for treatment of clostridioides difficile infections in Brazil: a single-center experience and risk factors for mortality [Internet]. Antibiotics-basel. 2022 ; 11( 9):[citado 2024 ago. 04 ] Available from: https://doi.org/10.3390/antibiotics11091162Vancouver
Alves JDF, Yamaguti A, Mendonca JS de, Gamba C de M, Fonseca CL, Paraskevopoulos DKS, Paula AI de, Hosino N, Costa SF, Guimaraes T. Metronidazole for treatment of clostridioides difficile infections in Brazil: a single-center experience and risk factors for mortality [Internet]. Antibiotics-basel. 2022 ; 11( 9):[citado 2024 ago. 04 ] Available from: https://doi.org/10.3390/antibiotics11091162